Integra LifeSciences Q1 adjusted EPS $0.74 beats prior year; raises FY organic growth guidance to 3.8%-5.2%

INTEGRA LIFESCIENCES HOLDINGS CORP

2022-Q1 EPS reported $0.39 revenue$376,638,000

Revenues $376.6M (+4.6% reported, +5.6% organic); adjusted EPS $0.74 vs $0.69 Q1 2021; GAAP EPS $0.39 (down from $0.53, prior year included $42.9M divestiture gain).
Codman Specialty Surgical rev $247.3M (org +5.0%); Tissue Technologies $129.3M (org +6.9%).
FY 2022 organic growth guidance raised to 3.8%-5.2% (from 3.5%-5.0%); reported revenue reaffirmed $1.58B-$1.60B; adjusted EPS reaffirmed $3.27-$3.35.
Board authorized new $225M share repurchase program (expires Dec 2024), replacing prior $225M program; completed $125M ASR in Q1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.